Reviva Pharmaceuticals Holdings, Inc. (RVPH) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 6 Buy, 2 Hold.
Analysts estimate Earnings Per Share (EPS) of $-19.71 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.90 vs est $-19.71 (beat +95.4%). 2025: actual $-5.48 vs est $-6.34 (beat +13.5%). Analyst accuracy: 0%.
RVPH Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Reviva Pharmaceuticals Holdings, Inc. in the past 3 months
EPS Estimates — RVPH
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.90
vs Est –$19.71
▲ 2,090.5% off
2025
Actual –$5.48
vs Est –$6.34
▲ 15.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — RVPH
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
